Fulgent Genetics: Buybacks and Insider Buying Signal Confidence Amidst Declining Stock

What happened

Fulgent Genetics' stock has fallen to around $15, well below tangible book value, triggering opportunistic share repurchases at $15.42 and insider purchases that underscore management's conviction. While the deep value thesis previously flagged an attractive entry at $22, the current price widens the margin of safety given net assets per share of $24–$29 and a $788M cash cushion. However, the company still grapples with 23% customer concentration, ongoing operating losses, and legal uncertainties from HRSA and DOJ investigations. The path to revaluation depends on sustaining mid-teens growth in precision diagnostics and controlling 2026 investment spend without margin erosion. For patient investors, the stock offers a compelling risk/reward if execution holds, but near-term catalysts remain limited pending FY2025 results and 2026 guidance.

Implication

For patient investors, the stock offers a compelling risk/reward with significant upside if diagnostics growth continues and operating losses narrow; monitor customer concentration and therapeutic spending.

Thesis delta

The stock has dropped from the $23.71 level to around $15, despite the deep value report's attractive entry at $22. This sharp decline, combined with aggressive share buybacks and insider purchases, suggests management sees extreme undervaluation. The investment thesis now hinges on whether the diagnostics business can sustain growth while the cash cushion provides downside protection.